Inclusion Criteria:  Aged 18 and over. Sufficiently fluent in English. Cytologically or pathologically verified diagnosis of renal cell carcinoma (RCC). Evidence of metastatic disease. Clinician assessed prognosis of greater than or equal to six months. Patients who are undergoing immunotherapy treatment (with a checkpoint inhibitor) for advanced kidney cancer who have grade 1 or 2 fatigue based on physician assessment at the time of study entry. Willing and independently able to provide consent.